Medindia

X

NVIDIA Tesla GPUs Help TechniScan Deliver Timely Breast Imaging Diagnostics

Thursday, March 11, 2010 General News J E 4
Advertisement


SALT LAKE CITY, March 11 TechniScan, Inc. (OTC Bulletin Board: TSNI) is featured on NVIDIA's recently posted blog about speeding the amount of time it takes to get breast imaging results into the hands of doctors and patients. NVIDIA is the world leader in visual computing technologies and inventor of the graphics processing unit (GPU).

TechniScan's Warm Bath Ultrasound (WBU(TM)) system utilizes NVIDIA Tesla GPUs to compute its complex algorithms used in creating 3 dimensional images of the breast.

"Waiting for medical results of diagnostic breast imaging is very stressful for women. The anxiety and stress can play havoc both mentally and physically," said David Robinson, chief executive officer at TechniScan. "NVIDIA Tesla GPUs have reduced the time it takes to process our data from 4.5 hours to less than 20 minutes."

As a result, women can get the results of their imaging while they are still at the hospital or clinic along with a review from their radiologist. Considering that more than 90 percent of suspicious spots or lesions are benign, many women can rest at ease after their ultrasound is negative for breast cancer.

Currently ultrasound is used as a secondary diagnostic imaging procedure when mammography is ambiguous on a breast lesion. Mammography can also miss some breast cancers, which makes products like the automated, whole breast, WBU(TM) technology from TechniScan even more relevant in breast imaging.

It's the sheer amount of information the WBU(TM) system gleans that is impressive. The scanner rotates all the way around a woman's breast, capturing a scan every 2 degrees, and then composites a detailed 3-D image. Each image is around 8 to 9 million voxels (the 3-D equivalent of a pixel) and requires more than 120 million Fast Fourier Transform (FFT) calculations to build.

"NVIDIA Tesla GPUs were twice as fast as our previous cluster solution and cost half as much," said Jim Hardwick, TechniScan's senior software engineer. "It's critical for us to deliver results while the patient is still at the clinic, and NVIDIA has made this possible."

NVIDIA Tesla GPUs are being used to tackle computational challenges in many fields, such as oil exploration, drug discovery and medical imaging. Its blog, nTersect, often profiles stories in these areas. View a full version of the approximately six minute video on TechniScan and NVIDIA collaborating to advance the diagnosis of breast cancer at http://blogs.NVIDIA.com/ntersect/2010/02/a-3d-ultrasound-for-better-cancer-detection.html.

About TechniScan, Inc.

Based in Salt Lake City, TechniScan, Inc. is a medical device company engaged in the development and commercialization of a non-invasive imaging tool designed to provide physicians with automated ultrasound images of the human breast. The system uses a process called Warm Bath Ultrasound (WBU (TM)) to provide physicians with automated, 3-D, ultrasound images of the physical structures within the breast. TechniScan's WBU(TM) imaging device is limited by U.S. law to investigational use unless, and until, cleared by the FDA. For more information, please visit www.techniscanmedical.com.

Forward Looking Statements

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate, "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "potential," "intend," and similar expressions. Such forward-looking statements, involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of TechniScan, Inc. (the "Company") to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov, including the Company's Current Report on Form 8-K filed on October 16th, 2009. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investment Banking Contact Jesup & Lamont Securities Corp. Mark Diamond 212-918-0415 mdiamond@jesuplamont.com David Bocchi 212-918-0472 dbocchi@jesuplamont.com

SOURCE TechniScan, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Peregrine Pharmaceuticals Reports Financial Result...
S
The Cancer Market Outlook To 2014: Competitive Lan...